Platelet activation in the prognosis of cardiovascular risks in patients with psoriasis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Psoriasis is a chronic inflammatory immune-dependent genodermatosis, mainly affecting the skin, with a prevalence in the population from 1 to 5%. The pathogenesis of psoriasis is based on Th1-dependent autoimmune inflammation, which leads to a change in the aggregation properties of platelets, increased excretion of thromboxane-A2, which worsens microcirculation processes and causes the development of endothelial dysfunction. Psoriasis is associated with a number of concomitant nosologies, such as psoriatic arthritis, depression, inflammatory bowel disease and cardiometabolic syndrome. Platelets play an important role in the development of cardiovascular diseases, as mediators of hemostasis. However, the number of publications on their pathophysiological contribution to the development of cardiovascular risks in patients with psoriasis is insignificant. Understanding the role of platelet activation in psoriasis and the correct choice of laboratory methods for their assessment will allow the timely prevention of vascular platelet disorders and prognosis.

Full Text

Restricted Access

About the authors

D. A. Shelamova

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: Darina.Shelamova@szgmu.ru
ORCID iD: 0000-0002-0539-9618

Post-graduate Student of the Biological and General Chemistry Department

Russian Federation, Kirochnaya st. 41, Saint-Petersburg, 191015

L. B. Gaikovaya

North-Western State Medical University named after I.I. Mechnikov

Email: Larisa.Gaikovaya@szgmu.ru
ORCID iD: 0000-0003-1000-1114

Dr Sc. (Med.), Professor of the Biological and General Chemistry Department

Russian Federation, Kirochnaya st. 41, Saint-Petersburg, 191015

References

  1. De Simonе C., Di Giorgio A., Sisto T., et al. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. Eur J Dermatol. 2011 Jul-Aug; 21(4): 510-514. doi: 10.1684/ejd.2011.1324.
  2. World Health Organization. Global Report on Psoriasis: World Health Organization, 2016. Accessed December 1, 2021; https://apps.who.int/iris/handle/10665/204417.
  3. Chang, Yun-Ting, Tzeng-Ji Chen, Pei-Chi Liu, et al. Epidemiological Study of Psoriasis in the National Health Insurance Database in Taiwan. Acta Derm Venereol. 2009; 89: 262–266.
  4. Parisi R., Symmons D.P., Griffiths C.E., et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J. Invest. Dermatol. 2013; 133: 377.
  5. Rahman P., Elder J.T. Genetic epidemiology of psoriasis and psoriatic. Ann Rheum Dis. 2005; 64: 37–39.
  6. Rachakonda T.D., Schupp C.W., Armstrong A.W. Psoriasis prevalence among adults in the United States. J. Am. Acad. Dermatol. 2014; 70 (3): 512–516. doi: 10.1016/j.jaad.2013.11.013
  7. Матушевская Е.В., Коновалова М.В., Владимирова Е.В., Свирщевская Е.В. Патогенез и терапия псориаза и псориатического артрита. Клиническая дерматология и венерология. [Matushevskaia E.V., Konovalova M.V., Vladimirova E.V., Svirshchevskaia E.V. Pathogenesis and therapy of psoriasis and psoriatic arthritis. Klinicheskaya Dermatologiya i Venerologiya. 2019; 18(5): 634–643. (In Russ.)]; https://doi.org/10.17116/klinderma201918051634.
  8. Viðié M., Kaštelan M., Brajac L., et al. Current concepts of psoriasis immunopathogenesis. Int. J. Mol. Sci. 2021; 22(21): 11574. doi: 10.3390/ijms222111574.
  9. Armstrong A.W., Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020.
  10. Garshick M.S., Ward N.L., Krueger J.G, Berger J.S. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021; 77(13): 1670–80. doi: 10.1016/j.jacc.2021.02.009
  11. Elmets C.A, Leonardi C.L., Davis D.M.R., et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J. Am. Acad. Dermatol.; 2019; 80(4): 1073–113. doi: 10.1016/j.jaad.2018.11.058.
  12. Samarasekera E.J., Neilson J.M., Warren R.B., et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J. Invest. Dermatol. 2013; 133(10): 2340–2346. doi: 10.1038/jid.2013.149.
  13. Мазуров А.В. Физиология и патология тромбоцитов. М.: Литерра, 2011. 248 с. [Mazurov A.V. Fiziologiya i patologiya trombocitov.М.: Literra, 2011. 248 s. (In Russ.)].
  14. Fan Z., Wang L., Jiang H., et al. Platelet dysfunction and its role in the pathogenesis of psoriasis. Dermatology. 2021; 237(1): 56–65. doi: 10.1159/000505536.
  15. Fuentes F., Palomo I., Fuentes E. Platelet oxidative stress as a novel target of cardiovascular risk in frail older people. Vascul Pharmacol. 2017; 93–95: 14–9. doi: 10.1016/j.vph.2017.07.003.
  16. Arnett D.K., Blumenthal R.S., Albert M.A., Buroker A.B., Goldberger Z.D., Hahn E.J., et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: A report of the American College of Cardiology/American heart association task force on clinical practice guidelines. J. Am. Coll. Cardiol. 2019; 74(10):1376–414. doi: 10.1016/j.jacc.2019.03.009
  17. Raghavan V., Radha R.K., Rao R.K., Kuberan A. A correlative study between platelet count, mean platelet volume and red cell distribution width with the disease severity index in psoriasis patients. J Clin Diagn Res. 2017; 11(9): EC13–6. doi: 10.7860/JCDR/2017/31172.10639.
  18. Korkmaz S. Mean platelet volume and platelet distribution width levels in patients with mild psoriasis vulgaris with metabolic syndrome. Postepy Dermatol Alergol. 2018; 35(4): 367–371. doi: 10.5114/ada.2017.71285.
  19. Capo A., Di Nicola M., Auriemma M., et al. Mean platelet volume variation after biologic therapy in psoriasis and psoriatic arthritis. Eur J Dermatol. 2014; 24(1): 133–135. doi: 10.1684/ejd.2014.2269.
  20. Sansanayudh N., Numthavaj P., Muntham D., et al. Prognostic effect of mean platelet volume in patients with coronary artery disease. A systematic review and meta-analysis. Thromb Haemost. 2015; 114(6): 1299–309. doi: 10.1160/TH15-04-0280.
  21. Chandrashekar L., Rajappa M., Revathy G., et al. Is enhanced platelet activation the missing link leading to increased cardiovascular risk in psoriasis? Clin. Chim. Acta. 2015; 446: 181–185. doi: 10.1016/j.cca.2015.04.023.
  22. Kim D.S., Lee J., Kim S.H., et al. Mean platelet volume is elevated in patients with psoriasis vulgaris. Yonsei Med. J. 2015; 56:712–8. doi: 10.3349/ymj.2015.56.3.712.
  23. Rechcinski T., Jasinska A., Forys J., et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. Cardiol. J. 2013; 20(5): 491–498. doi: 10.5603/CJ.2013.0134.
  24. Perkins L.A., Anderson C.J., Novelli E.M. Targeting P-selectin adhesion molecule in molecular imaging: P-selectin expression as a valuable imaging biomarker of inflammation in cardiovascular disease. J. Nucl. Med. 2019; 60(12): 1691–1697. doi: 10.2967/jnumed.118.225169.
  25. Kwiek B., Narbutt J., Sysa-Jedrzejowska A., et al. Long-term treatment of chronic plaque psoriasis with biological drugs can control platelet activation: targeting the bridge between inflammation and atherothrombosis. Postepy Dermatol. Alergol. 2017; 34(2): 131–137. doi: 10.5114/ada.2017.67077.
  26. Sirin M.C., Korkmaz S., Erturan I., et al. Evaluation of monocyte to HDL cholesterol ratio and other inflammatory markers in patients with psoriasis. Bras. Dermatol. 2020; 95(5): 575–582. doi: 10.1016/j.abd.2020.02.008.
  27. Шеламова Д.А., Гайковая Л.Б., Евтеева Д.А. Оценка риска формирования сосудисто-тромбоцитарных нарушений и развития тромботических осложнений у пациентов с псориазом по уровню экспрессии адгезивного Р-селек-тина и тромбоцитарных экзосом. Лабораторная диагностика. Восточная Европа. 2023; 12(2): 245–252; https://doi.org/10.34883/PI.2023.12.2.009. [Shelamova D.A., Gajkovaya L.B., Evteeva D.A. Ocenka riska formirovaniya sosudisto-trombocitarny`x narushenij i razvitiya tromboti-ches-kix oslozhnenij u pacientov s psoriazom po urovnyu e`kspressii adgezivnogo R-selektina i trombocitarny`x e`kzosom. Labo-ratornaya diagnostika. Vostochnaya Evropa. 2023; 12(2): 245–252; https://doi.org/10.34883/PI.2023.12.2.009. (In Russ.)].
  28. Garbaraviciene J., Diehl S., Varwig D., Bylaite M., et al. Platelet P-selectin reflects a state of cutaneous inflammation: possible application to monitor treatment efficacy in psoriasis. 21 July 2010; https://doi.org/10.1111/j.1600-0625.2010.01095.
  29. Blann A.D., Nadar S.K., Lip G.Y. The adhesion molecule P-selectin and cardiovascular disease. Eur. Heart. J. 2003; 24(24): 2166–2179. doi: 10.1016/j.ehj.2003.08.021.
  30. Сироткина О.В., Гайковая Л.Б., Вавилова Т.В. и др. Способ оценки эффективности действия антиагрегантных препа-ратов, влияющих на метаболизм арахидоновой кислоты путем ингибирования циклооксигеназы-1 как в отдель-ности, так и совместно с антагонистом рецептора АДФ P2Y12 на тромбоцитарных мембранах, на состояния тромбоцитов крови пациента, принимающего антиагреган-тные препараты указанной группы. Патент на изобретение RU 2442167 C1, 10.02.2012. Заявка № 2010130629/15 от 21.07.2010. [Sirotkina O.V., Gajkovaya L.B., Vavilova T.V., i dr. Sposob ocenki e`ffektivnosti dejstviya antiagregantny`x preparatov, vliyayushhix na metabolizm araxidonovoj kisloty` putem ingi-birovaniya ciklooksigenazy`-1 kak v otdel`nosti, tak i sov-mestno s antagonistom receptora ADF P2Y12 na tromboci-tarny`x membranax, na sostoyaniya trombocitov krovi pacienta, prinimayushhego antiagregantny`e preparaty` ukazannoj gruppy`. Patent na izobretenie RU 2442167 C1, 10.02.2012. Zayavka № 2010130629/15 ot 21.07.2010 (In Russ.)].
  31. Puhm F., Boilard E., Machlus K.R. Platelet extracellular vesicles: beyond the blood. Arterioscler Thromb Vasc Biol. 2021; 41(1): 87–96. doi: 10.1161/ATVBAHA.120.314644.
  32. Tamagawa-Mineoka R., Katoh N., Kishimoto S. Platelet activation in patients with psoriasis: increased plasma levels of platelet-derived microparticles and soluble P-selectin. J. Am. Acad. Dermatol. 2010; 62(4): 621–626. doi: 10.1016/j.jaad.2009.06.053.
  33. Гайковая Л.Б., Шеламова Д.А., Ермаков А.И. и др. Мик-рочастицы клеток крови как предиктор активации системы гемостаза у больных тяжелой формой псориаза. 2-я Все-российская научно-практическая конференция с между-народным участием. Изд-во СЗГМУ им. И.И. Мечникова, 2021; с. 231. [Gajkovaya L.B., Shelamova D.A., Ermakov A.I. i dr. Mikrochasticy kletok krovi kak prediktor aktivacii sistemy` gemostaza u bol`ny`x tyazheloj formoj psoriaza. 2-ya Vserossijskaya nauchno-prakticheskaya konferenciya s mezhdunarodny`m uchastiem. Izd-vo SZGMU im. I.I. Mechnikova, 2021; s. 231. (In Russ.)].
  34. Rosinska J., Lukasik M., Kozubski W. The impact of vascular disease treatment on platelet-derived microvesicles. Cardiovasc Drugs Ther. 2017; 31(5-6): 627–644. doi: 10.1007/s10557-017-6757-7.
  35. Garshick M.S., Barrett T.J., Wechter T., et al. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol. 2019; 39(4): 787–798. doi: 10.1161/ATVBAHA.118.312246.
  36. Sang Y., Roest M., de Laat B., et al. Interplay between platelets and coagulation. Blood Rev. 2021; 46: 100733. doi: 10.1016/j.blre.2020.100733.
  37. Upton J.E.M., Grunebaum E., Sussman G., Vadas P. Platelet activating factor (PAF): A mediator of inflammation. Biofactors. 2022; 48(6): 1189–1202. doi: 10.1002/biof.1883.
  38. Krause K., Gimenez-Arnau A., Martinez-Escala E., et al. Platelet-activating factor (PAF) induces wheal and flare skin reactions independent of mast cell degranulation. Allergy. 2013; 68(2): 256–258. doi: 10.1111/all.12083.
  39. Ramesha C.S., Soter N, Pickett W.C. Identification and quantitation of PAF from psoriatic scales. Agents Actions. 1987; 21(3-4): 382–383. doi: 10.1007/BF01966522.
  40. Andersen S., Sjursen W., Laegreid A., et al. Elevated expression of human nonpancreatic phospholipase A2 in psoriatic tissue. Inflammation. 1994; 18(1): 1–12. doi: 10.1007/BF01534593.
  41. Singh T.P., Huettner B., Koefeler H., et al. Platelet-activating factor blockade inhibits the T-helper type 17 cell pathway and suppresses psoriasis-like skin disease in K5.hTGF-beta1 transgenic mice. Am J Pathol. 2011; 178(2): 699–708. doi: 10.1016/j.ajpath.2010.10.008.
  42. Tsoupras A., Lordan R., Zabetakis I. Inflammation, not cholesterol, is a cause of chronic disease. Nutrients. 2018; 10: 604. doi: 10.3390/nu10050604.
  43. Cognasse F., Duchez A.C., Audoux E., et al. Platelets as key factors in inflammation: focus on CD40L/CD40. Front Immunol. 2022; 13: 825892. doi: 10.3389/fimmu.2022.825892.
  44. Peters A.L., Stunz L.L., Bishop G.A. CD40 and autoi-mmunity: the dark side of a great activator. Semin Immunol. 2009; 21(5): 293–300. doi: 10.1016/j.smim.2009.05.012.
  45. Zuchtriegel G., Uhl B., Puhr-Westerheide D., et al. Platelets guide leukocytes to their sites of extravasation. PloS Biol. 2016; 14(5): e1002459. doi: 10.1371/journal.pbio.1002459.
  46. Massberg S., Brand K., Gruner S., et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med. 2002; 196(7): 887–896. doi: 10.1084/jem.20012044.
  47. Medina-Leyte D.J., Zepeda-Garcia O., Dominguez-Perez M., et al. Endothelial dysfunction, inflammation and coronary artery disease: potential biomarkers and promising therapeutical approaches. Int J Mol Sci. 2021; 22(8): 3850. doi: 10.3390/ijms22083850.
  48. Coly P., Boulanger C. Extracellular Mitochondria and vesicles new mediators of endothelial inflammation. Circ. Res. 2019;125: 53–54.
  49. Role of mitochondria in the maintenance of platelet function during in vitro storage. Transfus. Med. 2011; 21: 166–174.
  50. Melchinger H., Jain K., Tyagi T., Hwa J. Role of platelet mitochondria: life in a nucleus-free zone. Front. Cardiovasc. Med. 2019; 6: 1–11.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Russkiy Vrach Publishing House

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies